Gilead Sciences is nearing a blockbuster acquisition of autoimmune disease-focused biotech Ouro Medicines for up to $2 billion, marking a strategic pivot as the California firm accelerates its dealmaking activity. The proposed deal would see Gilead pay $1.5 billion in upfront cash to Ouro’s investors, with an additional $500 million tied to clinical trial milestones, according to sources. Talks are advanced, with a potential announcement expected within days, though terms remain fluid. This follows Gilead’s recent $7.8 billion purchase of Arcellx, a cell therapy developer, signaling intensified M&A activity under CEO Daniel O’Day.

Ouro, founded in 2019, is developing an antibody therapy in early-stage trials targeting autoimmune conditions like lupus and rheumatoid arthritis. Its backers include private equity giant TPG, pharmaceutical giant GSK, and venture firm Monograph Capital, which led a $120 million funding round in January 2025. Gilead’s surge in dealmaking aligns with its post-pandemic resurgence, fueled by blockbuster HIV drugs like Biktarvy and a market cap of $170.5 billion, surpassing Pfizer’s. O’Day has emphasized prioritizing pipeline expansion through targeted acquisitions to offset looming patent expirations.

The move underscores Gilead’s push into autoimmune therapies, complementing its oncology focus. With $21 billion spent on Immunomedics in 2020 and $4.3 billion for CymaBay Therapeutics in 2024, the firm is leveraging its financial strength to bolster its R&D portfolio. Biotech sector consolidation has intensified as pharma giants race to secure innovative pipelines ahead of mass patent expirations.

Gilead’s aggressive strategy highlights the high-stakes nature of modern pharma dealmaking, where valuation volatility and competitive M&A tactics define corporate trajectories. The potential Ouro acquisition would not only expand Gilead’s autoimmune pipeline but also solidify its position as a leader in next-generation therapies.